



Suprenza™ (phentermine) – Drug Discontinuation

- [Citius Pharmaceuticals announced](#) the discontinuation of [Suprenza \(phentermine\)](#) 15 mg, 30 mg, and 37.5 mg orally disintegrating tablets.
 - The decision to discontinue Suprenza was for business reasons.
- Suprenza is indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index \geq to 30 kg/m², or \geq 27 kg/m² in the presence of other risk factors (eg, controlled hypertension, diabetes, hyperlipidemia).
 - The limited usefulness of agents of this class, including Suprenza, should be measured against possible risk factors inherent in their use.
 - Suprenza is a scheduled IV controlled substance.
- Phentermine is also available generically as [capsules](#) and [tablets](#).

Action Plan

- Information regarding Suprenza will be posted on the [optumrx.com](#) portals



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.